G-CSF Protein & Antibody (GCSF, CSF3)

Granulocyte-Colony Stimulating Factor (Colony Stimulating Factor 3)

G-CSF Products

G-CSF Protein, Recombinant

Molecule	Species	Description	Cat. No
G-CSF/CSF3	Human	G-CSF/CSF3/Fc (isoform b) Protein, Recombinant	10007-H01H
G-CSF/CSF3	Human	G-CSF/CSF3 (isoform b) Protein, Recombinant	10007-HNAE

  10007-HNAE:  ED₅₀= 0.022 ng / ml Measured in a cell proliferation assay using a murine myeloblastic cell line, NFS-60.

G-CSF Antibody

Molecule	Application	Description	Cat. No
Human G-CSF/CSF3	WB	Mouse Monoclonal Antibody	10007-MM05
Human G-CSF/CSF3	WB, ELISA	Rabbit Polyclonal Antibody	10007-RP01
Human G-CSF/CSF3	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	10007-RP02

G-CSF cDNA Clone

Molecule	Application	Description	Cat. No
G-CSF/CSF3	Human	Homo sapiens G-CSF/CSF3-alpha transcript variant 1 cDNA Clone(NM_000759.2)	HG10006-M
G-CSF/CSF3	Human	Homo sapiens G-CSF/CSF3 (isoform b) transcript variant 2 cDNA Clone(NM_172219.1)	HG10007-M

G-CSF Alternative Names

G-CSF, CSF3, GCSF, MGC45931 [Homo sapiens]

G-CSF, Csf3, Csfg, MGI-IG, RP23-395E10.4 [Mus musculus]

G-CSF Related Areas

Cancer>>Growth Factor & Receptor>>CSF & Receptor>>G-CSF/CSF3

Immunology>>Cytokine & Receptor>>CSF & Receptor>>G-CSF/CSF3

Immunology>>Cytokine & Receptor>>Interleukin & Receptor>>IL-6 Family Signaling Related Molecules>>G-CSF/CSF3

G-CSF Background

Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone-like glycoproteins. It is produced by numerous cell types including immune and endothelial cells. G-CSF binding to its receptor G-CSF-R which belongs to the cytokine receptor type I family depends on the interaction of alpha-helical motifs of the former and two fibronectin type III as well as an immunoglobulin-like domain of the latter. Recent animal studies have also revealed that G-CSF activates multiple signaling pathways, such as Akt and also the Janus family kinase-2 and signal transducer and activation of transcription-3 (Jak2-STAT3) pathway, thereby promoting survival, proliferation, differentiation and mobilisation of haematopoietic stem and progenitor cells. G-CSF is a cytokine that have been demonstrated to improve cardiac function and perfusion in myocardial infarction. And it was initially evaluated as a stem cell mobilizer and erythropoietin as a cytoprotective agent. G-CSF prevents left ventricular remodeling after myocardial infarction by decreasing cardiomyocyte death and by increasing the number of blood vessels, suggesting the importance of direct actions of G-CSF on the myocardium rather than through mobilization and differentiation of stem cells. Accordingly, recombinant human (rh)G-CSF has been extensively used in clinical haematology and oncology to enable bone marrow transplantation or to treat chemotherapy-associated neutropenia. In preclinical study, G-CSF improved cardiac function and perfusion by angiomyogenesis and protection of cardiomyocytes in myocardial infarction.

G-CSF Related Studies

1. Takano H, et al. (2007) G-CSF therapy for acute myocardial infarction. Trends Pharmacol Sci. 28(10): 512-7.
2. Klocke R, et al. (2008) Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications. Curr Med Chem. 15(10): 968-77.
3. Kang HJ, et al. (2008) G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction. Expert Rev Cardiovasc Ther. 6(5): 703-13.
4. Beekman R, et al. (2010) G-CSF and its receptor in myeloid malignancy. Blood. 115(25): 5131-6.